Gland PharmaNSE:GLAND +0.66%86 Return-on-Tangible-Equity is 14.73% as of Mar. 2026, which is 11% above its 10-year median of 13.32. GuruFocus rates NSE:GLAND with a GF Score™ of 86/100 and a GF Value™ of ₹2,132.00 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 895 Drug Manufacturers companies, Gland Pharma ranks better than 59.44% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Gland Pharma's annualized net income for the quarter that ended in Mar. 2026 was ₹14,667 Mil. Gland Pharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹99,555 Mil. Therefore, Gland Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 14.73%.
The historical rank and industry rank for Gland Pharma's Return-on-Tangible-Equity or its related term are showing as below:
NSE:GLAND'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.14 Med: 13.32 Max: 23.75
Current: 11.04
During the past 9 years, Gland Pharma's highest Return-on-Tangible-Equity was 23.75%. The lowest was 8.14%. And the median was 13.32%.
NSE:GLAND's Return-on-Tangible-Equity is ranked better than 59.44% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs NSE:GLAND: 11.04
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Gland Pharma Return-on-Tangible-Equity Related Terms
Gland Pharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Gland Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAND vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Gland Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.73% mean?
Gland Pharma (NSE:GLAND) has a Return-on-Tangible-Equity of 14.73% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gland Pharma and its competitors. This is 11% above median its historical median of 13.32. Over the past decade, Gland Pharma's Return-on-Tangible-Equity has ranged from 8.14 to 23.75. According to the industry distribution chart, Gland Pharma ranks #363 out of 895 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Gland Pharma's Return-on-Tangible-Equity too high?
Gland Pharma's current Return-on-Tangible-Equity of 14.73% is 11% above median its 10-year median of 13.32. Over the past 10 years, this metric has ranged from a low of 8.14 to a high of 23.75. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. Gland Pharma's value of 14.73% is 86.7% above this industry median. Based on the distribution chart, Gland Pharma ranks #363 out of 895 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gland Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #363 out of 895 companies for Return-on-Tangible-Equity. This puts Gland Pharma in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.89. Gland Pharma's value of 14.73% is 86.7% above this benchmark. Historically, Gland Pharma's own Return-on-Tangible-Equity has ranged from 8.14 to 23.75 over the past decade. While the company's 10-year median is 13.32 vs. the industry median of 7.89, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current Return-on-Tangible-Equity of 14.73% is 86.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current Return-on-Tangible-Equity is 14.73%, which is 11% above median its own 10-year median of 13.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,132.00, compared to a current price of ₹2,462.30 — trading 15.5% above its estimated fair value. The current Return-on-Tangible-Equity is 14.73%, which is 11% above median its 10-year median of 13.32 and 86.7% above the Drug Manufacturers industry median of 7.89. Gland Pharma's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Return-on-Tangible-Equity is 14.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,462.30 is trading 15.5% above its estimated GF Value™ of ₹2,132.00.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
Return-on-Tangible-Equity: 14.73% (11% above median its 10-year median of 13.32)
GF Value™: ₹2,132.00 vs. price of ₹2,462.30 (15.5% above fair value)
Industry Position: 86.7% above the Drug Manufacturers median (#363 of 895)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
86GF Score
Get the complete analysis for NSE:GLAND
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
